Subscribe
shutterstock_580492693_akedesign
akedesign / Shutterstock.com
10 December 2020Big PharmaMuireann Bolger

90% of essential medicines off-patent, study reveals

Only 10% of essential medicines recommended by the World Health Organisation are on patent, according to a report by research and advocacy organisation, the Geneva Network.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Asia
Takeda sheds off-patent drugs to focus on innovation
17 April 2017   Takeda will sell a number of its off-patent drugs, used for treatment of diabetes, hypertension and peptic ulcers, to Teva Takeda Yakuhin for ¥28.5 billion.
Big Pharma
Pfizer off-patent division to merge with Mylan
29 July 2019   Pfizer is to merge its off-patent drug business Upjohn with Mylan, in a deal that will see Pfizer shareholders own 57% of the new company.


Editor's picks

Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

Editor's picks

Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Americas
Litigation implications of the USPTO’s terminal disclaimer proposal
29 August 2024
Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Europe
Labour govt appoints new Minister with IP oversight
9 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024

More on this story

Asia
Takeda sheds off-patent drugs to focus on innovation
17 April 2017   Takeda will sell a number of its off-patent drugs, used for treatment of diabetes, hypertension and peptic ulcers, to Teva Takeda Yakuhin for ¥28.5 billion.
Big Pharma
Pfizer off-patent division to merge with Mylan
29 July 2019   Pfizer is to merge its off-patent drug business Upjohn with Mylan, in a deal that will see Pfizer shareholders own 57% of the new company.

More on this story

Asia
Takeda sheds off-patent drugs to focus on innovation
17 April 2017   Takeda will sell a number of its off-patent drugs, used for treatment of diabetes, hypertension and peptic ulcers, to Teva Takeda Yakuhin for ¥28.5 billion.
Big Pharma
Pfizer off-patent division to merge with Mylan
29 July 2019   Pfizer is to merge its off-patent drug business Upjohn with Mylan, in a deal that will see Pfizer shareholders own 57% of the new company.

More features

Gilead scores win in fake HIV drug dispute
Polsinelli grows roster with ex-corporate counsel
‘Don’t rely on national case law’ at the UPC: Wouter Pors, Bird & Bird
Sandoz wins $137.2m payout for lost profits in generic launch
Sanofi signs global rights deal to develop rare cancer therapy
Unified Patent Court visualised: Cases, divisions, and classes in charts
WBD to merge with firm to create ‘powerhouse’ practice
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers